[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506633":3},{"organization":4,"armGroups":7,"interventions":40,"overallOfficials":114,"centralContacts":118,"locations":128,"responsibleParty":168,"collaborators":76,"id":170,"slug":171,"hasResults":172,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":76,"eligibilityCriteria":176,"healthyVolunteers":177,"sex":178,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":76,"studyType":184,"phases":185,"briefSummary":187,"conditions":188,"keywords":76,"overallStatus":131,"whyStopped":76,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,20,25,32,36],{"label":9,"type":10,"description":11,"interventionNames":12},"Aim 1 (vitals, spirometry, CPET, blood samples, DEXA)","EXPERIMENTAL","Participants undergo measurement of height\u002Fweight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study.",[13,14,15,16,17,18,19],"Procedure: Biospecimen Collection","Other: Cardiopulmonary Exercise Testing","Procedure: Dual X-ray Absorptiometry","Other: Electronic Health Record Review","Procedure: Physical Examination","Other: Questionnaire Administration","Procedure: Spirometry",{"label":21,"type":10,"description":22,"interventionNames":23},"Aim 2 (aerobic based training program, Aim 1 activities)","CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.",[13,14,15,16,24,17,18,19],"Other: Exercise Intervention",{"label":26,"type":27,"description":28,"interventionNames":29},"Aims 3-4 arm I (indolent NHL usual care)","ACTIVE_COMPARATOR","Indolent NHL patients undergo measurement of height\u002Fweight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients receive usual care on study.",[13,14,15,16,17,18,19,30,31],"Other: Physical Performance Testing","Other: Best Practice",{"label":33,"type":27,"description":34,"interventionNames":35},"Aims 3-4 arm II (indolent NHL aerobic based training program)","Indolent NHL patients undergo measurement of height\u002Fweight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.",[13,14,15,16,24,17,18,19,30,31],{"label":37,"type":10,"description":38,"interventionNames":39},"Aim 5 (repeat baseline activities)","All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.",[13,14,15,16,17,18,19,30],[41,50,57,72,77,81,93,96,100,107],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"PROCEDURE","Biospecimen Collection","Undergo collection of blood",[9,21,37,26,33],[47,48,49],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"Cardiopulmonary Exercise Testing","Undergo CPET",[9,21,37,26,33],[55,56],"CPET","CPX",{"type":42,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Dual X-ray Absorptiometry","Undergo DEXA scan",[9,21,37,26,33],[62,63,64,65,66,67,68,69,70,71],"BMD scan","bone mineral density scan","DEXA","DEXA (Bone Density)","DEXA Scan","dual energy x-ray absorptiometric scan","Dual Energy X-ray Absorptiometry","Dual X-Ray Absorptometry","DXA","DXA SCAN",{"type":6,"name":73,"description":74,"armGroupLabels":75,"otherNames":76},"Electronic Health Record Review","Ancillary studies",[9,21,37,26,33],null,{"type":6,"name":78,"description":79,"armGroupLabels":80,"otherNames":76},"Exercise Intervention","Undergo aerobic based training program",[21,33],{"type":42,"name":82,"description":83,"armGroupLabels":84,"otherNames":85},"Physical Examination","Undergo measurement of height\u002Fweight and vital signs",[9,21,37,26,33],[86,87,88,89,90,91,92],"Assessment","General Examination","Physical","Physical Assessment","Physical Exam","Physical examination procedure (procedure)","physical_exam",{"type":6,"name":94,"description":74,"armGroupLabels":95,"otherNames":76},"Questionnaire Administration",[9,21,37,26,33],{"type":42,"name":97,"description":98,"armGroupLabels":99,"otherNames":76},"Spirometry","Undergo spirometry",[9,21,37,26,33],{"type":6,"name":101,"description":102,"armGroupLabels":103,"otherNames":104},"Physical Performance Testing","Undergo muscular strength and functional endurance measurements",[37,26,33],[105,106],"Physical Fitness Testing","Physical Function Testing",{"type":6,"name":108,"description":109,"armGroupLabels":110,"otherNames":111},"Best Practice","Receive usual care",[26,33],[112,113],"standard of care","standard therapy",[115],{"name":116,"affiliation":5,"role":117},"Michael P. Gustafson, PhD","PRINCIPAL_INVESTIGATOR",[119,124],{"name":120,"role":121,"phone":122,"phoneExt":76,"email":123},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":125,"role":121,"phone":126,"phoneExt":76,"email":127},"Courtney Wheatley-Guy, PhD","480-301-8976","wheatley.courtney@mayo.edu",[129,150],{"facility":130,"status":131,"city":132,"state":133,"zip":134,"country":135,"countryCode":136,"cosmosGeoPoint":137,"geoPoint":142,"contacts":143},"Mayo Clinic in Arizona","RECRUITING","Scottsdale","Arizona","85259","United States","US",{"type":138,"coordinates":139},"Point",[140,141],-111.89903,33.50921,{"lat":141,"lon":140},[144,145,149],{"name":120,"role":121,"phone":122,"phoneExt":76,"email":123},{"name":146,"role":121,"phone":147,"phoneExt":76,"email":148},"Jordan Parks","480-301-6616","parks.jordan@mayo.edu",{"name":116,"role":117,"phone":76,"phoneExt":76,"email":76},{"facility":151,"status":131,"city":152,"state":153,"zip":154,"country":135,"countryCode":136,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Mayo Clinic in Rochester","Rochester","Minnesota","55905",{"type":138,"coordinates":156},[157,158],-92.4699,44.02163,{"lat":158,"lon":157},[161,162,166],{"name":120,"role":121,"phone":122,"phoneExt":76,"email":123},{"name":163,"role":121,"phone":164,"phoneExt":76,"email":165},"Briana Ziegler","507-255-7125","zeigler.briana@mayo.edu",{"name":167,"role":117,"phone":76,"phoneExt":76,"email":76},"Neil E. Kay, M.D.",{"type":169,"investigatorFullName":76,"investigatorTitle":76,"investigatorAffiliation":76,"oldNameTitle":76,"oldOrganization":76},"SPONSOR","100506633","the-effects-of-exercise-on-immune-phenotype-of-indolent-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-patients-100506633",false,"NCT05876923","The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients","The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients","Inclusion Criteria:\n\n* English speaking\n* Between the ages of 18-80\n* Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL\u002FSLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study\n\nExclusion Criteria:\n\n* Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease \\[COPD\\], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker\n* Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate",true,"ALL","18 Years","80 Years",{"count":182,"type":183},70,"ESTIMATED","INTERVENTIONAL",[186],"NA","This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.",[189,190],"Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Indolent Non-hodgkin Lymphoma","2026-04-06",{"date":193,"type":194},"2026-04-09","ACTUAL",{"date":196,"type":194},"2023-06-12",{"date":198,"type":183},"2028-04",{"name":5,"class":6},2]